Profile data is unavailable for this security.
About the company
Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
- Revenue in EUR (TTM)804.00k
- Net income in EUR-20.11m
- Incorporated2012
- Employees11.00
- LocationGensight Biologics SA74 Rue du Faubourg Saint-AntoinePARIS 75012FranceFRA
- Phone+33 176217220
- Fax+33 176217221
- Websitehttps://www.gensight-biologics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Predilife SA | 317.79k | -4.22m | 14.20m | 19.00 | -- | -- | -- | 44.69 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
Plant Advanced Technologies PAT SA | 2.53m | 1.09m | 14.37m | 27.00 | 12.94 | -- | 9.11 | 5.67 | 0.9967 | 0.9967 | 2.32 | -- | -- | -- | -- | 93,777.41 | -- | -3.53 | -- | -4.39 | 110.03 | 134.21 | 43.01 | -33.16 | -- | 12.90 | -- | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
Poxel SA | 1.98m | -35.09m | 14.41m | 22.00 | -- | -- | -- | 7.27 | -1.08 | -1.08 | 0.0591 | -1.27 | 0.1002 | -- | 5.09 | 90,045.45 | -177.50 | -52.39 | -- | -92.20 | 0.0505 | -- | -1,771.33 | -299.15 | -- | -1.39 | -- | -- | 193.92 | -49.84 | -11.76 | -- | -- | -- |
Phaxiam Therapeutics SA | 2.14m | -21.92m | 18.39m | 54.00 | -- | 0.7219 | -- | 8.59 | -3.46 | -3.46 | 0.3956 | 2.54 | 0.0409 | -- | 8.56 | 41,980.39 | -41.90 | -50.69 | -61.11 | -66.25 | -- | -- | -1,023.96 | -1,009.09 | -- | -70.91 | 0.4556 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
Valbiotis SA | 527.00k | -8.94m | 18.42m | 52.00 | -- | 1.09 | -- | 34.95 | -0.6571 | -0.6571 | 0.0373 | 1.07 | 0.0208 | 2.52 | 0.2447 | 10,134.62 | -35.21 | -32.92 | -46.61 | -46.36 | -511.95 | 53.15 | -1,697.15 | -418.87 | 4.54 | -91.62 | 0.266 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
Oncodesign Precision Medicine Opm SA | 468.73k | -7.78m | 19.65m | 19.00 | -- | 6.23 | -- | 41.91 | -0.449 | -0.449 | 0.0269 | 0.1733 | 0.0311 | -- | 0.4553 | 21,305.91 | -51.68 | -- | -85.27 | -- | 153.18 | -- | -1,660.23 | -- | -- | -360.87 | 0.715 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
Nfl Biosciences SAS | 0.00 | -2.37m | 19.99m | 4.00 | -- | 5.75 | -- | -- | -0.2653 | -0.2653 | 0.00 | 0.3584 | 0.00 | -- | -- | 0.00 | -44.70 | -83.27 | -70.88 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -53.28 | -- | -- | -- |
Fermentalg SA | 8.04m | -14.14m | 27.14m | 58.00 | -- | 0.7075 | -- | 3.38 | -0.2787 | -0.2787 | 0.1521 | 0.4452 | 0.1395 | 1.34 | 4.82 | 129,629.00 | -22.80 | -21.94 | -25.70 | -24.71 | 14.04 | 14.73 | -163.46 | -248.95 | 3.42 | -53.95 | 0.2639 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
genOway SA | 21.42m | 1.26m | 33.57m | 128.00 | 25.23 | 1.78 | 8.96 | 1.57 | 0.1435 | 0.1435 | 2.45 | 2.04 | 0.6658 | 1.39 | 3.26 | 161,089.30 | 3.90 | 0.2166 | 5.40 | 0.3048 | 92.34 | 94.82 | 5.86 | 0.4177 | 1.81 | -- | 0.2639 | -- | 17.55 | 13.16 | 101.55 | 22.35 | -14.31 | -- |
Gensight Biologics SA | 804.00k | -20.11m | 35.60m | 11.00 | -- | -- | -- | 44.28 | -0.3537 | -0.3537 | 0.0123 | -0.2402 | 0.0507 | -- | 21.73 | 50,250.00 | -126.79 | -79.44 | -- | -144.54 | -- | -- | -2,501.00 | -1,036.27 | -- | -1,250.38 | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
Novacyt SA | 22.42m | -45.13m | 43.87m | 240.00 | -- | 0.5154 | -- | 1.96 | -0.639 | -0.6438 | 0.3175 | 1.21 | 0.1603 | -3.66 | 1.02 | 83,040.82 | -32.27 | 10.94 | -38.44 | 14.49 | 153.78 | 61.98 | -201.27 | 17.64 | 3.82 | -23.91 | 0.1573 | -- | -44.97 | -0.9408 | -25.22 | -- | 2.09 | -- |
Abionyx Pharma SA | 4.86m | -3.36m | 47.44m | 61.00 | -- | 4.63 | -- | 9.77 | -0.1063 | -0.1063 | 0.1548 | 0.2934 | 0.3316 | 21.80 | 6.05 | 80,264.46 | -22.93 | -18.82 | -33.15 | -28.87 | 19.19 | 14.32 | -69.15 | -128.54 | 2.22 | -114.07 | 0.2513 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
Eurofins-Cerep SA | 42.42m | 7.25m | 97.35m | 218.00 | 13.42 | 1.44 | 10.53 | 2.30 | 1,438.10 | 1,438.10 | 8,415.76 | 13,378.57 | 0.5618 | 1.52 | 5.41 | 186,032.70 | 9.61 | 14.21 | 11.08 | 17.51 | 85.48 | 73.61 | 17.10 | 19.77 | 6.89 | -- | 0.0047 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Gensight Biologics SA's reporting currency: Euro EUR
Holder | Shares | % Held |
---|---|---|
Invus Public Equities Advisors LLCas of 31 Dec 2023 | 8.36m | 7.91% |
Armistice Capital LLCas of 18 Sep 2024 | 3.66m | 3.46% |
Amiral Gestion SAas of 31 Dec 2023 | 1.50m | 1.42% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 43.37k | 0.04% |
Financi�re Arbevel SAas of 30 Dec 2022 | 0.00 | 0.00% |
DWS Investment GmbHas of 31 Dec 2022 | 0.00 | 0.00% |
More ▼
Data from 29 Dec 2023 - 30 Aug 2024Source: FactSet Research Systems Inc.